Directorate Change

RNS Number : 2094E

Manx Financial Group PLC

07 February 2018

 

IMMEDIATE RELEASE                                                                                       7 February 2018

Manx Financial Group PLC

(the "Group")

Board Appointment

The board of Manx Financial Group PLC is delighted to announce the appointment of Dr Greg Bailey as a Non-Executive Director with immediate effect.

Greg Bailey, M.D., founded Palantir Group Inc which made successful investments in bio-tech company start-ups and financings, and is currently chairman of Portage Biotech Inc, a CSE-traded drug development company, and non-executive director of AIM-traded SalvaRx Group Plc.  Along with comprehensive experience in finance and healthcare, Greg has served on many public company boards and brings to the Group an extensive involvement in corporate governance.

Denham Eke commented: "We welcome Greg to the Board, and look forward to benefiting from his breadth of knowledge as well as his understanding of financing and investments".                                                                                                            

Current and past Directorships for Gregory Hugh Bailey, aged 62, are set out below:

Current: SalvaRx Group Plc Biohaven Pharmaceuticals Holding Company Limited iWin Inc. DuraMedic Inc. Portage Biotech Inc. Chelsea Avondale Holdings (Canada) Inc. 1783485 Ontario Inc. Topix Inc. Chelsea Avondale Limited MediqVentures Limited Palantir Group Inc. Culminant Capital Inc. Culminant Media Inc. Culminant Media Inc. Go to Ground Inc. Juvenescence Limited Juvenescence AI Limited Topix Pharma Inc.

Past: Plethora Solutions Holdings Plc Medivation Inc. Life for Children Foundation Sentien Biotechnologies Inc. Secure Axcess LLC Trojantec Limited Prism Technologies LLC Trojantec Technologies

Dr Bailey is indirectly interested in 17,835,750 ordinary shares, representing 13.60% of the issued share capital of Manx Financial Group PLC. 

There is no further information relating to Dr Bailey required to be disclosed under Schedule Two, (g) (i)-(viii).

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014

For further information, please contact:

Manx Financial Group PLC

Denham Eke, Chief Executive

Tel:  [phone]

Beaumont Cornish Limited

Roland Cornish/James Biddle

Tel:  [phone]

Britton Financial PR

Tim Blackstone

Tel: [phone]

 

END

 

 

BOAUGUMUPUPRGWM